Teiyi Pharmaceutical Group Co., Ltd.
Teyi Pharmaceutical Group Co., Ltd. (hereinafter referred to as Teyi Pharmaceutical) is a pharmaceutical listed company (stock code 002728) integrating pharmaceutical research and development, pharmaceutical industry, and pharmaceutical commerce. Its subordinate enterprises are distributed in Guangdong, Hainan, Anhui and other regions. Teyi Pharmaceutical and its wholly-owned subsidiary Hainan Haili Pharmaceutical Co., Ltd. and Taishan Xinning Pharmaceutical Co., Ltd. are both national high-tech enterprises. Teyi Pharmaceutical has been successively rated as "Outstanding Contributor Enterprise in the Pharmaceutical Industry in Guangdong Province", "Netherlands Science and Technology Enterprise in Guangdong Province", "Netherlands Innovation Industrialization Demonstration Base", "Netherlands Innovation Enterprise in Guangdong Province", and "Abide by Contracts and Harmony Credit enterprises", "A-level taxpayer", "AA-level credit-grade customer", etc.; Hainan Haili Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Teyi Pharmaceutical, has been successively rated as "National Intellectual Property Advantage Enterprise in 2018" and "Hainan Leading enterprises in the industrial industry (Chinese patent medicine manufacturing industry)", "national quality, service, and reputation AAA enterprises" and "A-level taxpayers", etc. Teyi Pharmaceutical industry includes Taishan pharmaceutical production base (formerly Guangdong Taicheng Pharmaceutical), Haikou pharmaceutical production base (Hainan Haili Pharmaceutical Co., Ltd.), raw material pharmaceutical production base (Taishan Xinning Pharmaceutical Co., Ltd.) and chemical product production base (Taishan Chemical Factory Co., Ltd.). Teyi Pharmaceutical Group's products include Chinese patent medicines, chemical preparations, chemical raw materials and chemical products. Among them, the "Special One" brand series covers cough and phlegm relief, kidney nourishment, anti-infection, cardiovascular and cerebrovascular and digestive system medications, among which the main preparation products include cough and anti-inflammatory tablets, Pudilan anti-inflammatory tablets, Xuesaitong dispersed tablets, Yixinshu Granules, Ginkgo Leaf Dispersion Tablets, Jinkui Shen Qi Tablets, Magnesium Aluminum Carbonate Chewable Tablets, Erythromycin Enteric Coated Tablets, Erythromycin Tablets, Rorythromycin Capsules, Amoxicillin Capsules, Omeprazole Enteric-coated capsules, etc.; the main chemical raw materials and chemical products include magnesium aluminum carbonate, sodium phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc. Teyi Pharmaceutical's core product is cough-relieving tablets. Its secret recipe was included in the Lingnan Traditional Chinese Medicine Cultural Heritage Protection List (the first batch) in 2009 and was recognized as a key new product in Guangdong Province in 2012; a wholly-owned subsidiary Taishan Xinning Pharmaceutical The key products produced by the Co., Ltd. are magnesium aluminum carbonate, sodium phenytoin, glacial acetic acid, calcium chloride and other raw materials, and are ranked among the top in the national market share. Sodium chloride for injection and bismuth nitrate for basic use have been awarded the "National Medical Administration's high-quality product". In 2018, Teyi Pharmaceutical added pills and eye drops through asset acquisition. The main varieties of pills include Xuedu Pills, Xiaozhu Pills, Tongmai Zhanzhi Pills, Ruyi Dingpan Pills, Wulin Pills, Anti-Tube Pills, Menstrual Freckle Pills, etc. The main products of eye drops include compound dextran 70 eye drops wait. At the same time, the original product combination has also been enriched, such as the respiratory system, including Pudilan anti-inflammatory tablets, Hanhuangling Granules, Xiqingguo Granules, etc., the digestive system, Fengliao Intestine Weakang Tablets, etc., and Zhuangyao Jianshen Pills in Buyi. , Bushen Banlong Capsules, etc. have improved the segmentation of the product line for Teyi Pharmaceutical and also provided guarantees for the segmentation and refined promotion of sales channels. Teyi Pharmaceutical Group currently has two nationwide sales and commercial platforms, among which Guangdong Teyi Haili Pharmaceutical Co., Ltd. operates the "Teyi" brand series produced by Teyi Pharmaceutical Industry. Another commercial platform is Hainan Haili Doctor Pharmaceutical Group Co., Ltd., which operates OEM products of the "Haili Doctor" brand and adopts regional agency sales across the country, including Chinese patent medicines and chemical preparations, and is also diversified by Teyi Pharmaceutical. , an important support for the development of professional value-added business direction. In the future, Teyi Pharmaceutical will continue to adhere to the corporate purpose of "focusing on quality, strengthening R&D, and sustainable development", with endogenous growth as the core and external growth as the auxiliary, strengthen resource integration and internal potential tapping, and strive to build excellent brands and maintain the enterprise. and become a competitive pharmaceutical company.
Teiyi Pharmaceutical Group Co., Ltd.
Teyi Pharmaceutical Group Co., Ltd. (hereinafter referred to as Teyi Pharmaceutical) is a pharmaceutical listed company (stock code 002728) integrating pharmaceutical research and development, pharmaceutical industry, and pharmaceutical commerce. Its subordinate enterprises are distributed in Guangdong, Hainan, Anhui and other regions. Teyi Pharmaceutical and its wholly-owned subsidiary Hainan Haili Pharmaceutical Co., Ltd. and Taishan Xinning Pharmaceutical Co., Ltd. are both national high-tech enterprises. Teyi Pharmaceutical has been successively rated as "Outstanding Contributor Enterprise in the Pharmaceutical Industry in Guangdong Province", "Netherlands Science and Technology Enterprise in Guangdong Province", "Netherlands Innovation Industrialization Demonstration Base", "Netherlands Innovation Enterprise in Guangdong Province", and "Abide by Contracts and Harmony Credit enterprises", "A-level taxpayer", "AA-level credit-grade customer", etc.; Hainan Haili Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Teyi Pharmaceutical, has been successively rated as "National Intellectual Property Advantage Enterprise in 2018" and "Hainan Leading enterprises in the industrial industry (Chinese patent medicine manufacturing industry)", "national quality, service, and reputation AAA enterprises" and "A-level taxpayers", etc. Teyi Pharmaceutical industry includes Taishan pharmaceutical production base (formerly Guangdong Taicheng Pharmaceutical), Haikou pharmaceutical production base (Hainan Haili Pharmaceutical Co., Ltd.), raw material pharmaceutical production base (Taishan Xinning Pharmaceutical Co., Ltd.) and chemical product production base (Taishan Chemical Factory Co., Ltd.). Teyi Pharmaceutical Group's products include Chinese patent medicines, chemical preparations, chemical raw materials and chemical products. Among them, the "Special One" brand series covers cough and phlegm relief, kidney nourishment, anti-infection, cardiovascular and cerebrovascular and digestive system medications, among which the main preparation products include cough and anti-inflammatory tablets, Pudilan anti-inflammatory tablets, Xuesaitong dispersed tablets, Yixinshu Granules, Ginkgo Leaf Dispersion Tablets, Jinkui Shen Qi Tablets, Magnesium Aluminum Carbonate Chewable Tablets, Erythromycin Enteric Coated Tablets, Erythromycin Tablets, Rorythromycin Capsules, Amoxicillin Capsules, Omeprazole Enteric-coated capsules, etc.; the main chemical raw materials and chemical products include magnesium aluminum carbonate, sodium phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth series, citric acid series, zinc sulfate, etc. Teyi Pharmaceutical's core product is cough-relieving tablets. Its secret recipe was included in the Lingnan Traditional Chinese Medicine Cultural Heritage Protection List (the first batch) in 2009 and was recognized as a key new product in Guangdong Province in 2012; a wholly-owned subsidiary Taishan Xinning Pharmaceutical The key products produced by the Co., Ltd. are magnesium aluminum carbonate, sodium phenytoin, glacial acetic acid, calcium chloride and other raw materials, and are ranked among the top in the national market share. Sodium chloride for injection and bismuth nitrate for basic use have been awarded the "National Medical Administration's high-quality product". In 2018, Teyi Pharmaceutical added pills and eye drops through asset acquisition. The main varieties of pills include Xuedu Pills, Xiaozhu Pills, Tongmai Zhanzhi Pills, Ruyi Dingpan Pills, Wulin Pills, Anti-Tube Pills, Menstrual Freckle Pills, etc. The main products of eye drops include compound dextran 70 eye drops wait. At the same time, the original product combination has also been enriched, such as the respiratory system, including Pudilan anti-inflammatory tablets, Hanhuangling Granules, Xiqingguo Granules, etc., the digestive system, Fengliao Intestine Weakang Tablets, etc., and Zhuangyao Jianshen Pills in Buyi. , Bushen Banlong Capsules, etc. have improved the segmentation of the product line for Teyi Pharmaceutical and also provided guarantees for the segmentation and refined promotion of sales channels. Teyi Pharmaceutical Group currently has two nationwide sales and commercial platforms, among which Guangdong Teyi Haili Pharmaceutical Co., Ltd. operates the "Teyi" brand series produced by Teyi Pharmaceutical Industry. Another commercial platform is Hainan Haili Doctor Pharmaceutical Group Co., Ltd., which operates OEM products of the "Haili Doctor" brand and adopts regional agency sales across the country, including Chinese patent medicines and chemical preparations, and is also diversified by Teyi Pharmaceutical. , an important support for the development of professional value-added business direction. In the future, Teyi Pharmaceutical will continue to adhere to the corporate purpose of "focusing on quality, strengthening R&D, and sustainable development", with endogenous growth as the core and external growth as the auxiliary, strengthen resource integration and internal potential tapping, and strive to build excellent brands and maintain the enterprise. and become a competitive pharmaceutical company.
Gansu Minhai Pharmaceutical Co., Ltd.
Introduction to Gansu Minhai Pharmaceutical Co., Ltd. Gansu Minhai Pharmaceutical Co., Ltd. is located in the Minxian Industrial Park, the "Millennium Pharmaceutical Township" in southern Gansu, covering an area of 60,000 square meters. The company focuses on the research and development, production and sales of Chinese patent medicines. It has 6 production lines: pills, tablets, capsules, and granules, and 32 national drug-approved font varieties. There are 66 production technology R&D personnel, and the proportion of employees with college degree or above accounts for 65%. The total assets are 320 million yuan, the annual production capacity is 200,000 pieces, and the total output value reaches 500 million yuan. In recent years, the company has combined cultural construction with product quality construction, and has always adhered to the principle of "people-oriented, morally oriented, quality-winning, and honesty-seeking trust", and "integrity and dedication, innovation and progress, serving customers, and serving society" For the corporate spirit, with the corporate value concept of "fully respecting customers' pursuits and jointly creating greater value", and with the goal of "developing traditional medicines in the motherland and serving human health", we will ultimately implement "Minhai Pharmaceuticals and create medicines for the people" corporate social responsibility. A relatively complete product quality assurance system has been established and a complete management system, process procedures and operating procedures have been formulated. Passed the national GMP certification. We must ensure that all levels of quality control are achieved from the source of materials, production process, quality inspection, product sales, market control and other aspects, and seamless monitoring of all aspects of product quality to ensure that the factory products are 100% qualified and the safety of the people's medication. The company has always regarded inheriting and carrying forward the traditional Chinese medicine industry in the motherland as its historical mission. Chairman Zhang Feng was responsible for the establishment of a traditional Chinese medicine studio with 44 people. The main tasks of the studio are: First, inheriting and learning traditional Chinese medicine theoretical knowledge. , let everyone have a basic understanding and understanding of traditional Chinese medicine, which is conducive to the inheritance and popularization of traditional Chinese medicine knowledge, so that everyone can master the use of traditional Chinese medicine knowledge for self-care, and be able to use the basic knowledge of traditional Chinese medicine you have learned for simple Treatment mainly involves promoting and promoting traditional Chinese medicine knowledge to the public; the second is to learn, inherit and inherit traditional Chinese medicine preparation methods. The preparation methods of traditional Chinese medicine directly affect the efficacy of Chinese patent medicines. It must be prepared according to ancient methods; the third is to discover and innovate classical and experienced prescriptions, and develop classical prescriptions for the treatment of many difficult and complicated diseases. Since its establishment, the Traditional Chinese Medicine Studio has completed the research and development of many new products. The nursing product for cervical syndrome, Shunkang-liquid dressing has been successfully launched. This product is very effective in the nursing of cervical syndrome through experiments on a large number of people, and the market prospects are very good. Optimistic; Products for treating lumbar disc herniation: Yaojian—Liquid dressing has been successfully registered and the product will be launched soon; other new scientific research products will be launched one after another, including women's warm palace food: Xinjiang Zhiyuan Food, damp-removing products: Jingu Food Granules; Treatment of psoriasis Products: hemorrhoids hemorrhoids; products for hemorrhoids: hemorrhoids; hair loss: silky black hair; blood pressure reduction: Dandan granules, mountain flower crystal granules, etc. The new products developed have been applied for and protected invention patents; Fourth, the Chinese medicine practitioners are trained through traditional Chinese medicine inheritance, and in the future they will become qualified Chinese medicine practitioners who can cure diseases and save lives. The company will establish the Minhai Traditional Chinese Medicine Health Center National Chain as an important tool for the inheritance of traditional Chinese medicine.
Gansu Minhai Pharmaceutical Co., Ltd.
Introduction to Gansu Minhai Pharmaceutical Co., Ltd. Gansu Minhai Pharmaceutical Co., Ltd. is located in the Minxian Industrial Park, the "Millennium Pharmaceutical Township" in southern Gansu, covering an area of 60,000 square meters. The company focuses on the research and development, production and sales of Chinese patent medicines. It has 6 production lines: pills, tablets, capsules, and granules, and 32 national drug-approved font varieties. There are 66 production technology R&D personnel, and the proportion of employees with college degree or above accounts for 65%. The total assets are 320 million yuan, the annual production capacity is 200,000 pieces, and the total output value reaches 500 million yuan. In recent years, the company has combined cultural construction with product quality construction, and has always adhered to the principle of "people-oriented, morally oriented, quality-winning, and honesty-seeking trust", and "integrity and dedication, innovation and progress, serving customers, and serving society" For the corporate spirit, with the corporate value concept of "fully respecting customers' pursuits and jointly creating greater value", and with the goal of "developing traditional medicines in the motherland and serving human health", we will ultimately implement "Minhai Pharmaceuticals and create medicines for the people" corporate social responsibility. A relatively complete product quality assurance system has been established and a complete management system, process procedures and operating procedures have been formulated. Passed the national GMP certification. We must ensure that all levels of quality control are achieved from the source of materials, production process, quality inspection, product sales, market control and other aspects, and seamless monitoring of all aspects of product quality to ensure that the factory products are 100% qualified and the safety of the people's medication. The company has always regarded inheriting and carrying forward the traditional Chinese medicine industry in the motherland as its historical mission. Chairman Zhang Feng was responsible for the establishment of a traditional Chinese medicine studio with 44 people. The main tasks of the studio are: First, inheriting and learning traditional Chinese medicine theoretical knowledge. , let everyone have a basic understanding and understanding of traditional Chinese medicine, which is conducive to the inheritance and popularization of traditional Chinese medicine knowledge, so that everyone can master the use of traditional Chinese medicine knowledge for self-care, and be able to use the basic knowledge of traditional Chinese medicine you have learned for simple Treatment mainly involves promoting and promoting traditional Chinese medicine knowledge to the public; the second is to learn, inherit and inherit traditional Chinese medicine preparation methods. The preparation methods of traditional Chinese medicine directly affect the efficacy of Chinese patent medicines. It must be prepared according to ancient methods; the third is to discover and innovate classical and experienced prescriptions, and develop classical prescriptions for the treatment of many difficult and complicated diseases. Since its establishment, the Traditional Chinese Medicine Studio has completed the research and development of many new products. The nursing product for cervical syndrome, Shunkang-liquid dressing has been successfully launched. This product is very effective in the nursing of cervical syndrome through experiments on a large number of people, and the market prospects are very good. Optimistic; Products for treating lumbar disc herniation: Yaojian—Liquid dressing has been successfully registered and the product will be launched soon; other new scientific research products will be launched one after another, including women's warm palace food: Xinjiang Zhiyuan Food, damp-removing products: Jingu Food Granules; Treatment of psoriasis Products: hemorrhoids hemorrhoids; products for hemorrhoids: hemorrhoids; hair loss: silky black hair; blood pressure reduction: Dandan granules, mountain flower crystal granules, etc. The new products developed have been applied for and protected invention patents; Fourth, the Chinese medicine practitioners are trained through traditional Chinese medicine inheritance, and in the future they will become qualified Chinese medicine practitioners who can cure diseases and save lives. The company will establish the Minhai Traditional Chinese Medicine Health Center National Chain as an important tool for the inheritance of traditional Chinese medicine.
Guangdong Xinbao Pharmaceutical Technology Co., Ltd.
Guangdong Xinbao Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") is a national high-tech enterprise focusing on the research, development, production and sales of traditional Chinese medicine drugs. The company implements the value of "benevolent and honest, to make benevolent medicine, to be kind and embrace talents, and to value confidence and develop together", adheres to the business philosophy of "honest and trustworthy, win-win cooperation", and is based on the treatment fields such as cardiovascular, respiratory, and digestive. , with pharmaceutical manufacturing as its core business, adhere to the development path of dual-wheel drive of R&D innovation and marketing innovation, gradually form a sustainable development business system with Chinese patent medicine as its business basis, leading the innovation of big health products, and is determined to achieve "building a century-old heart treasure" , benefit the people of the world”. The company has 5 subsidiaries, covering pharmaceutical, trade, technology research and development, big health, commercial services and other sectors. In 2019, the company invested in the construction of the second and third phases of industry, academia and research bases to build a two-way consortium cooperation model that integrates talent training, scientific research and development, and technological achievements transformation cooperation. Relying on the core regional advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, The company strives to build a "four new" big health industry and research highland with innovative technologies, innovative industries, innovative business formats and innovative models. The company adheres to the development concept of "science and technology research and development is the primary productive force", strives to build an innovative scientific research platform, and actively carries out industry-university-research cooperation with various universities and research institutes. In 2017, the company was approved to establish the "Guangdong Province Xinbao Mingyou Chinese Patent Medicine Engineering Technology Research Center" and presided over the provincial project "Second Development Research of Famous High-quality Chinese Patent Medicine Xinbao Pills". The company cooperates with the Guangdong Provincial Drug Inspection Institute to carry out the research project on the formulation and revision of drug standards of the National Pharmacopeia Commission "Improving the Quality Standards of Xinbao Pills". The company produces multiple dosage form products such as pills, tablets, capsules, granules; among them, Xingchen brand "Xinbao Pills" have been sold well in the market for more than 30 years. Its prescription is special, its efficacy is accurate, and it is safe to take. In 2015, the Xingchen Brand Guilu Shen Budding Tablets, which the company has devoted itself to, became a chain terminal supplement incremental product. At the same time, the Pudilan anti-inflammatory series products produced by the company have been favored by partners and consumers with their excellent product quality and good efficacy, and have become a well-known brand of "Traditional Medicine Antibiotics". The company implements the business strategy of "full products, all terminals, and all channels", builds a chronic disease product system based on the core theory of "heart and kidney treatment", deepens its efforts in the terminal pharmaceutical market, increases county-level terminal coverage, and innovates professional academic promotion system , empower the marketing system with the help of digital channels and intelligent marketing platforms. Guangdong Xinbao Pharmaceutical Technology Co., Ltd. will always be committed to the cause of human health, strive to provide patients with high-quality health products, provide employees with a career development platform, provide partners with win-win opportunities for collaboration, work together and witness the wonderful future!
Guangdong Xinbao Pharmaceutical Technology Co., Ltd.
Guangdong Xinbao Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") is a national high-tech enterprise focusing on the research, development, production and sales of traditional Chinese medicine drugs. The company implements the value of "benevolent and honest, to make benevolent medicine, to be kind and embrace talents, and to value confidence and develop together", adheres to the business philosophy of "honest and trustworthy, win-win cooperation", and is based on the treatment fields such as cardiovascular, respiratory, and digestive. , with pharmaceutical manufacturing as its core business, adhere to the development path of dual-wheel drive of R&D innovation and marketing innovation, gradually form a sustainable development business system with Chinese patent medicine as its business basis, leading the innovation of big health products, and is determined to achieve "building a century-old heart treasure" , benefit the people of the world”. The company has 5 subsidiaries, covering pharmaceutical, trade, technology research and development, big health, commercial services and other sectors. In 2019, the company invested in the construction of the second and third phases of industry, academia and research bases to build a two-way consortium cooperation model that integrates talent training, scientific research and development, and technological achievements transformation cooperation. Relying on the core regional advantages of the Guangdong-Hong Kong-Macao Greater Bay Area, The company strives to build a "four new" big health industry and research highland with innovative technologies, innovative industries, innovative business formats and innovative models. The company adheres to the development concept of "science and technology research and development is the primary productive force", strives to build an innovative scientific research platform, and actively carries out industry-university-research cooperation with various universities and research institutes. In 2017, the company was approved to establish the "Guangdong Province Xinbao Mingyou Chinese Patent Medicine Engineering Technology Research Center" and presided over the provincial project "Second Development Research of Famous High-quality Chinese Patent Medicine Xinbao Pills". The company cooperates with the Guangdong Provincial Drug Inspection Institute to carry out the research project on the formulation and revision of drug standards of the National Pharmacopeia Commission "Improving the Quality Standards of Xinbao Pills". The company produces multiple dosage form products such as pills, tablets, capsules, granules; among them, Xingchen brand "Xinbao Pills" have been sold well in the market for more than 30 years. Its prescription is special, its efficacy is accurate, and it is safe to take. In 2015, the Xingchen Brand Guilu Shen Budding Tablets, which the company has devoted itself to, became a chain terminal supplement incremental product. At the same time, the Pudilan anti-inflammatory series products produced by the company have been favored by partners and consumers with their excellent product quality and good efficacy, and have become a well-known brand of "Traditional Medicine Antibiotics". The company implements the business strategy of "full products, all terminals, and all channels", builds a chronic disease product system based on the core theory of "heart and kidney treatment", deepens its efforts in the terminal pharmaceutical market, increases county-level terminal coverage, and innovates professional academic promotion system , empower the marketing system with the help of digital channels and intelligent marketing platforms. Guangdong Xinbao Pharmaceutical Technology Co., Ltd. will always be committed to the cause of human health, strive to provide patients with high-quality health products, provide employees with a career development platform, provide partners with win-win opportunities for collaboration, work together and witness the wonderful future!
Anhui Jiren Pharmaceutical Co., Ltd.
Anhui Jiren Pharmaceutical Co., Ltd. is located in Bozhou City, Anhui Province. It was established in April 2001. It has now developed into a modern way of integrating standardized planting of medicinal materials, Chinese herbal medicines, Chinese herbal formula granules and Chinese patent medicine research and development, production and sales. Traditional Chinese medicine pharmaceutical company. The company has four wholly-owned subsidiaries, namely Anhui Hongfang Pharmaceutical Co., Ltd., Anhui Puren Traditional Chinese Medicine Decoction Co., Ltd., Anhui Pukang Traditional Chinese Medicine Resources Co., Ltd., and Anhui Jiren Pharmaceutical Group Traditional Chinese Medicine Research Institute Co., Ltd. Since its establishment, the company attaches great importance to industry, academia and research cooperation, and has established good cooperative relations with many universities and research institutes such as the Chinese Academy of Traditional Chinese Medicine, Tianjin Institute of Pharmaceuticals, Anhui University of Traditional Chinese Medicine, Anhui Medical University, Shanghai University of Traditional Chinese Medicine and other universities and research institutes. , the academician workstation, the national and local joint engineering research center, the provincial postdoctoral research workstation and the provincial enterprise technology center have been established. In terms of traditional Chinese patent medicines, the company has a total of 35 varieties of drug approval numbers, including Shufeng Jiedu Capsules, Pudilan Anti-inflammatory Tablets, Tongbing Ling Capsules, and Pentyan Jing Tablets. Shufeng Jiedu Capsule was selected as the "Research Project on Clinical Evaluation and Drug Resistance in the Treatment of Acute Severe Stage of Chronic Obstructive Pulmonary In 2019, and was registered as a compound Chinese medicine in the UK. In 2022, the registration application for Shufeng Jiedu Capsule in Hong Kong was approved by the Hong Kong Traditional Chinese Medicine Administration Commission. In terms of traditional Chinese medicine formula granules, the company is an enterprise in Anhui Province that has obtained the GMP certification of traditional Chinese medicine formula granules. With more than ten years of innovative R&D accumulation, relying on the "Anhui Provincial Traditional Chinese Medicine Formula Granules Engineering Technology Research Center" and "Anhui Provincial Technology Innovation Center for Traditional Chinese Medicine Extraction" and so on. As a traditional Chinese medicine innovation platform, the company has achieved the research and development and sales of more than 500 traditional Chinese medicine formula granules. Since 2019, the company's 128 Chinese medicine formula granules have successfully passed the EU's QP inspection, obtained the "Export EU Raw Materials Certificate" and achieved exports to EU regions such as Germany. In terms of traditional Chinese herbal medicines, the company sells more than 700 kinds of traditional Chinese herbal medicines.
Anhui Jiren Pharmaceutical Co., Ltd.
Anhui Jiren Pharmaceutical Co., Ltd. is located in Bozhou City, Anhui Province. It was established in April 2001. It has now developed into a modern way of integrating standardized planting of medicinal materials, Chinese herbal medicines, Chinese herbal formula granules and Chinese patent medicine research and development, production and sales. Traditional Chinese medicine pharmaceutical company. The company has four wholly-owned subsidiaries, namely Anhui Hongfang Pharmaceutical Co., Ltd., Anhui Puren Traditional Chinese Medicine Decoction Co., Ltd., Anhui Pukang Traditional Chinese Medicine Resources Co., Ltd., and Anhui Jiren Pharmaceutical Group Traditional Chinese Medicine Research Institute Co., Ltd. Since its establishment, the company attaches great importance to industry, academia and research cooperation, and has established good cooperative relations with many universities and research institutes such as the Chinese Academy of Traditional Chinese Medicine, Tianjin Institute of Pharmaceuticals, Anhui University of Traditional Chinese Medicine, Anhui Medical University, Shanghai University of Traditional Chinese Medicine and other universities and research institutes. , the academician workstation, the national and local joint engineering research center, the provincial postdoctoral research workstation and the provincial enterprise technology center have been established. In terms of traditional Chinese patent medicines, the company has a total of 35 varieties of drug approval numbers, including Shufeng Jiedu Capsules, Pudilan Anti-inflammatory Tablets, Tongbing Ling Capsules, and Pentyan Jing Tablets. Shufeng Jiedu Capsule was selected as the "Research Project on Clinical Evaluation and Drug Resistance in the Treatment of Acute Severe Stage of Chronic Obstructive Pulmonary In 2019, and was registered as a compound Chinese medicine in the UK. In 2022, the registration application for Shufeng Jiedu Capsule in Hong Kong was approved by the Hong Kong Traditional Chinese Medicine Administration Commission. In terms of traditional Chinese medicine formula granules, the company is an enterprise in Anhui Province that has obtained the GMP certification of traditional Chinese medicine formula granules. With more than ten years of innovative R&D accumulation, relying on the "Anhui Provincial Traditional Chinese Medicine Formula Granules Engineering Technology Research Center" and "Anhui Provincial Technology Innovation Center for Traditional Chinese Medicine Extraction" and so on. As a traditional Chinese medicine innovation platform, the company has achieved the research and development and sales of more than 500 traditional Chinese medicine formula granules. Since 2019, the company's 128 Chinese medicine formula granules have successfully passed the EU's QP inspection, obtained the "Export EU Raw Materials Certificate" and achieved exports to EU regions such as Germany. In terms of traditional Chinese herbal medicines, the company sells more than 700 kinds of traditional Chinese herbal medicines.
Shandong Kongfu Pharmaceutical Co., Ltd.
Shandong Kongfu Pharmaceutical Co., Ltd. is located in Qufu City, a historical and cultural city and the hometown of Confucius. It is affiliated to Shandong Yulong Mining Group Co., Ltd. It is a key enterprise for Yulong Group to adjust its industrial structure and promote its transformation and development. It is a specialized in the production of Chinese patent medicines and chemical medicines. A technology-intensive modern pharmaceutical enterprise for raw materials and preparation products. The company has existing assets of 80 million yuan, and all production lines passed the national drug GMP certification in November 2008. In 2005, it was recognized as a "high-tech enterprise" by the Provincial Department of Science and Technology. The company's products are mainly made up of traditional Chinese patent medicine OTC products, with seven dosage forms, including oral liquid, syrup, granules, tablets, capsules, pills, and powders, including "Niuhuang Snake Dan Chuanbei Liquid" and "Greatinian Granules "It is a national protected variety of traditional Chinese medicine. The company's traditional Chinese medicine department products are mainly Chinese patent medicine OTC products, with 6 dosage forms and 39 varieties. The leading varieties include beef yellow snake gallbladder Chuanbei liquid, gastritis granules, wind-cold, wind-heat cold granules, orange red granules, Pudilan anti-inflammatory tablets and other products. Yulong Pharmaceutical Industrial Park (Ministry of Chemical Pharmaceuticals), built a high-standard production workshop and laboratory in 2012. In cooperation with Beijing Haibu Pharmaceutical Technology Co., Ltd., it introduced a number of first-line anti-tumor and cardiovascular and cerebrovascular treatments with international advanced levels. Varieties include erlotinib hydrochloride, pitavastatin calcium, and amrisintan. The company actively carries out the transformation of new and old kinetic energy, solidly promotes the construction of key projects, and completes the expansion project of the new oral liquid workshop, the transformation project of oral solid preparation workshop, and the pretreatment and extraction project of traditional Chinese medicine. The company's product sales have spread across the country, and beef yellow snake gallbladder Sichuan shell liquid, wind-cold cold granules, etc. have become well-known regional products. The concept of "pinning the source of the simplicity" and "a medicine of benevolence" and the "Kongfu" brand with a profound Confucian culture have become unique advantages for the long-term development of Kongfu Pharmaceutical.
Shandong Kongfu Pharmaceutical Co., Ltd.
Shandong Kongfu Pharmaceutical Co., Ltd. is located in Qufu City, a historical and cultural city and the hometown of Confucius. It is affiliated to Shandong Yulong Mining Group Co., Ltd. It is a key enterprise for Yulong Group to adjust its industrial structure and promote its transformation and development. It is a specialized in the production of Chinese patent medicines and chemical medicines. A technology-intensive modern pharmaceutical enterprise for raw materials and preparation products. The company has existing assets of 80 million yuan, and all production lines passed the national drug GMP certification in November 2008. In 2005, it was recognized as a "high-tech enterprise" by the Provincial Department of Science and Technology. The company's products are mainly made up of traditional Chinese patent medicine OTC products, with seven dosage forms, including oral liquid, syrup, granules, tablets, capsules, pills, and powders, including "Niuhuang Snake Dan Chuanbei Liquid" and "Greatinian Granules "It is a national protected variety of traditional Chinese medicine. The company's traditional Chinese medicine department products are mainly Chinese patent medicine OTC products, with 6 dosage forms and 39 varieties. The leading varieties include beef yellow snake gallbladder Chuanbei liquid, gastritis granules, wind-cold, wind-heat cold granules, orange red granules, Pudilan anti-inflammatory tablets and other products. Yulong Pharmaceutical Industrial Park (Ministry of Chemical Pharmaceuticals), built a high-standard production workshop and laboratory in 2012. In cooperation with Beijing Haibu Pharmaceutical Technology Co., Ltd., it introduced a number of first-line anti-tumor and cardiovascular and cerebrovascular treatments with international advanced levels. Varieties include erlotinib hydrochloride, pitavastatin calcium, and amrisintan. The company actively carries out the transformation of new and old kinetic energy, solidly promotes the construction of key projects, and completes the expansion project of the new oral liquid workshop, the transformation project of oral solid preparation workshop, and the pretreatment and extraction project of traditional Chinese medicine. The company's product sales have spread across the country, and beef yellow snake gallbladder Sichuan shell liquid, wind-cold cold granules, etc. have become well-known regional products. The concept of "pinning the source of the simplicity" and "a medicine of benevolence" and the "Kongfu" brand with a profound Confucian culture have become unique advantages for the long-term development of Kongfu Pharmaceutical.
Hunan FangSheng Pharmaceutical Co., Ltd.
Founded in June 2002, Fangsheng Pharmaceutical is a high-quality, comprehensive, scientific research-based pharmaceutical and health industry group integrating pharmaceutical industry, medical services and big health businesses. It has many subsidiaries, December 5, 2014. It was successfully listed on the Shanghai Stock Exchange on the day and officially entered the capital market (stock code: 603998). From the establishment of the factory to the present, Fang Sheng has risen rapidly with a steady development speed and has grown into a benchmark enterprise in the pharmaceutical industry in Hunan Province. Fang Sheng takes "Your health, Fang Sheng's pursuit" as the corporate mission. Over the past 10 years, it has been constantly exploring, trying and developing in all fields of big health, always committed to serving human health, and building a pharmaceutical industry as the The main body, with medical services and big health (health consumption, elderly care) as the strategic layout of "one body and two wings". In the pharmaceutical industry, Fangsheng Pharmaceutical Headquarters is the main body, and its subsidiary Xiangya Pharmaceuticals, Hainan Boda, Sanhua Pharmaceuticals, etc. are assisted in the joint development; at the same time, it will quickly promote the construction of Fangsheng Lip's international factory to create a way that can meet both the FDA and the NMPA. International technology platform to accelerate integration with the international market; in terms of the medical industry, relying on the two industrial funds investment targets of Baijun Medical and Kexin Health, the company's participation in investment, to meet the people's growing growth in the two major areas of kidney disease and tumors. Health service needs; in terms of healthy elderly care, using Xiangya Pharmaceutical's "Xiangya Xileyuan" as a carrier to create an elderly care life model that combines "nursing homes" and "rizhao centers" to promote the company's development layout in the elderly care industry. Fang Sheng takes "new drug research and development capabilities" as the company's core competitive advantage, integrates the advantages of global new drug research and development resources, forms a high-level R&D team, and establishes three drugs, "Traditional medicine, chemical medicine, and biological medicine", using the imitation of complex chemical preparations, Improvement and innovation and product R&D strategies with internationalization as important characteristics have been continuously promoted to the "1+N" model of internationalized large-scale R&D system, achieving integrated development in multiple technologies and fields. In the field of traditional Chinese medicine, Fang Sheng has successfully developed several major brand series products such as Xinxuean brand cardiovascular and cerebrovascular department, Jinbeibei brand pediatrics, Meiershu brand gynecology, and Fangshengtang brand orthopedic department. In the field of chemical drugs, Fang Sheng is committed to focusing on the development of blockbuster drugs for the prevention and treatment of major diseases. The first phase I clinical trial of Deantecon sodium for injection of the Class 1 anti-cancer drug independently developed by its subsidiary Fang Sheng Huamei is about to be completed. The Phase I clinical trial of Lipo in the United States is about to be completed. Paclitaxel for injection (albumin-binding type) has completed the preliminary research and development work. In the field of biopharmaceuticals, the "National Engineering Research Center for Genetic Engineering Drugs" of Jida Genetics has successfully passed the acceptance, and its future development prospects are broad. At present, Fang Sheng has achieved the management of the entire value chain of pharmaceutical research, clinical research, consistency evaluation, production and sales in the field of new drug research and development. The company now has a nationally certified enterprise technology center and a postdoctoral research workstation. It undertakes major national new drug creation science and technology projects and a number of provincial and ministerial science and technology projects. It has obtained more than 160 drug production approval documents, nearly 20 new drug certificates, and nearly 40 invention patents. , 2 international patents, rich product reserves, provide strong support for realizing Fangsheng strategy and meeting people's health needs. Fang Sheng has formed a professional marketing team, and the marketing network covers hospitals, chains, single pharmacies and clinics at all levels in provinces and cities across the country. With excellent product quality and professional and high-quality services, it has established the Fang Sheng brand in the field of medicine. The company fully promotes professional and academic marketing, and through diversified academic activities, we work with medical institutions at all levels to jointly improve China's overall medical level. Fang Sheng has multiple production bases in Changsha, Hainan, Liaoning, Yunnan and other places. He organizes production strictly in accordance with the requirements of the new version of GMP and excellent performance system, establishes a complete quality control and assurance system, and implements the quality management of the entire process and all employees. Ensure the quality and safety of people's medication use. Among them, Fangsheng Pharmaceutical Industrial Park, located in Changsha Hi-tech Zone, covers an area of 150 mu and has a total construction area of 230,000 square meters, providing strong support for the company's production capacity required in its strategic development. In the future, Fangsheng will continue to take the pharmaceutical industry as the main body, strengthen the core competitive advantages of new drug research and development, and leverage the power of capital to leverage the development of the industry, and ultimately realize the "one body and two wings" strategic layout of the pharmaceutical industry, medical services, and healthy elderly care, and create high-quality, Comprehensive and scientific research-based pharmaceutical and health industry aircraft carriers realize Fang Sheng’s dream and achieve the dream of health!
Hunan FangSheng Pharmaceutical Co., Ltd.
Founded in June 2002, Fangsheng Pharmaceutical is a high-quality, comprehensive, scientific research-based pharmaceutical and health industry group integrating pharmaceutical industry, medical services and big health businesses. It has many subsidiaries, December 5, 2014. It was successfully listed on the Shanghai Stock Exchange on the day and officially entered the capital market (stock code: 603998). From the establishment of the factory to the present, Fang Sheng has risen rapidly with a steady development speed and has grown into a benchmark enterprise in the pharmaceutical industry in Hunan Province. Fang Sheng takes "Your health, Fang Sheng's pursuit" as the corporate mission. Over the past 10 years, it has been constantly exploring, trying and developing in all fields of big health, always committed to serving human health, and building a pharmaceutical industry as the The main body, with medical services and big health (health consumption, elderly care) as the strategic layout of "one body and two wings". In the pharmaceutical industry, Fangsheng Pharmaceutical Headquarters is the main body, and its subsidiary Xiangya Pharmaceuticals, Hainan Boda, Sanhua Pharmaceuticals, etc. are assisted in the joint development; at the same time, it will quickly promote the construction of Fangsheng Lip's international factory to create a way that can meet both the FDA and the NMPA. International technology platform to accelerate integration with the international market; in terms of the medical industry, relying on the two industrial funds investment targets of Baijun Medical and Kexin Health, the company's participation in investment, to meet the people's growing growth in the two major areas of kidney disease and tumors. Health service needs; in terms of healthy elderly care, using Xiangya Pharmaceutical's "Xiangya Xileyuan" as a carrier to create an elderly care life model that combines "nursing homes" and "rizhao centers" to promote the company's development layout in the elderly care industry. Fang Sheng takes "new drug research and development capabilities" as the company's core competitive advantage, integrates the advantages of global new drug research and development resources, forms a high-level R&D team, and establishes three drugs, "Traditional medicine, chemical medicine, and biological medicine", using the imitation of complex chemical preparations, Improvement and innovation and product R&D strategies with internationalization as important characteristics have been continuously promoted to the "1+N" model of internationalized large-scale R&D system, achieving integrated development in multiple technologies and fields. In the field of traditional Chinese medicine, Fang Sheng has successfully developed several major brand series products such as Xinxuean brand cardiovascular and cerebrovascular department, Jinbeibei brand pediatrics, Meiershu brand gynecology, and Fangshengtang brand orthopedic department. In the field of chemical drugs, Fang Sheng is committed to focusing on the development of blockbuster drugs for the prevention and treatment of major diseases. The first phase I clinical trial of Deantecon sodium for injection of the Class 1 anti-cancer drug independently developed by its subsidiary Fang Sheng Huamei is about to be completed. The Phase I clinical trial of Lipo in the United States is about to be completed. Paclitaxel for injection (albumin-binding type) has completed the preliminary research and development work. In the field of biopharmaceuticals, the "National Engineering Research Center for Genetic Engineering Drugs" of Jida Genetics has successfully passed the acceptance, and its future development prospects are broad. At present, Fang Sheng has achieved the management of the entire value chain of pharmaceutical research, clinical research, consistency evaluation, production and sales in the field of new drug research and development. The company now has a nationally certified enterprise technology center and a postdoctoral research workstation. It undertakes major national new drug creation science and technology projects and a number of provincial and ministerial science and technology projects. It has obtained more than 160 drug production approval documents, nearly 20 new drug certificates, and nearly 40 invention patents. , 2 international patents, rich product reserves, provide strong support for realizing Fangsheng strategy and meeting people's health needs. Fang Sheng has formed a professional marketing team, and the marketing network covers hospitals, chains, single pharmacies and clinics at all levels in provinces and cities across the country. With excellent product quality and professional and high-quality services, it has established the Fang Sheng brand in the field of medicine. The company fully promotes professional and academic marketing, and through diversified academic activities, we work with medical institutions at all levels to jointly improve China's overall medical level. Fang Sheng has multiple production bases in Changsha, Hainan, Liaoning, Yunnan and other places. He organizes production strictly in accordance with the requirements of the new version of GMP and excellent performance system, establishes a complete quality control and assurance system, and implements the quality management of the entire process and all employees. Ensure the quality and safety of people's medication use. Among them, Fangsheng Pharmaceutical Industrial Park, located in Changsha Hi-tech Zone, covers an area of 150 mu and has a total construction area of 230,000 square meters, providing strong support for the company's production capacity required in its strategic development. In the future, Fangsheng will continue to take the pharmaceutical industry as the main body, strengthen the core competitive advantages of new drug research and development, and leverage the power of capital to leverage the development of the industry, and ultimately realize the "one body and two wings" strategic layout of the pharmaceutical industry, medical services, and healthy elderly care, and create high-quality, Comprehensive and scientific research-based pharmaceutical and health industry aircraft carriers realize Fang Sheng’s dream and achieve the dream of health!
Tianjin Pharmaceutical Daren Tang Group Co., Ltd.
Sino-Singapore Tianjin Longshunrong Pharmaceutical Factory was founded in 1833. Longshunrong Pharmacy has become the leader in "Western" medicine for its excellent quality, excellent management and outstanding reputation. In 1957, Longshunrong and Lerentang Refining Department merged to form a professional manufacturer of traditional Chinese medicine extraction preparations, namely China New Pharmaceutical Tianjin Longshunrong Pharmaceutical Factory. On the basis of inheriting the fine traditions, Sino-Singapore Pharmaceutical Factory has been constantly innovating and exporting to Hong Kong, Macao, Taiwan, Singapore and Malaysia. It was once the export base of Tianjin’s Chinese patent medicines, and 21 Chinese patent medicine manufacturers across the country. one. For many years, Sino-Singapore Tianjin Longshunrong Pharmaceutical Factory has been focusing on the exploration of traditional Chinese medicine dosage form reform and the research on traditional Chinese medicine technology, and is the birthplace of the modernization of Chinese traditional Chinese medicine. It has set a precedent in the history of traditional Chinese medicine in scientific research and development, quality management, production and operation, talent citation, etc.: It established a Chinese patent medicine research institution and a national Chinese medicine refining department nationwide in 1952, and introduced a doctorate studying abroad in the history of the Chinese medicine industry. Combining traditional Chinese medicine theory with modern preparation technology to study the reform of Chinese medicine dosage form, we developed the Chinese patent medicine tablet - Yinqiao Jiedu Tablets; Chinese patent medicine tincture - Huoxiang Zhengqi Water; Chinese medicine granules - Danggui Sini Decoction; Traditional Chinese medicine injections-Jinchanlisu and other new Chinese medicine dosage forms. In terms of software construction: Sino-Singapore Tianjin Longshunrong Pharmaceutical Factory is a Chinese patent medicine manufacturer in Tianjin that promotes standardized production of all varieties of standard operation books in production quality management, forming the earliest software prototype of Chinese traditional Chinese medicine pharmaceutical companies. . Currently, Sino-Singapore Tianjin Longshunrong Pharmaceutical Factory has three production lines: liquid agent, tablet and granule, and 88 registered varieties. Under the new development situation, Sino-Singapore Pharmaceutical Tianjin Longshunrong Pharmaceutical Factory has established the corporate survival concept of " making high-quality Chinese medicine products and creating national quintessential brands ", and advocates the corporate culture with "development" as the core on the basis of integrity. Advocate the concept of " honesty management " in sales work; advocate the concept of "quality first" in production work; advocate the concept of "innovative development" in technical work; advocate the concept of "people-oriented" in human resources management work. In the development plan, the enterprise proposes: advocate a corporate culture with "innovation" as the core to maximize corporate value; provide high-quality products and services, create health for mankind and wealth for society; be responsible for employees to meet the needs of employees' lives and growth, Enable its material and spiritual interests to realize; devote themselves to social welfare undertakings, become a caring enterprise, and reflect the social value of the enterprise; inherit the culture of health medicine and create a strong brand of "Longshunrong". Longshunrong has established a reasonable talent structure to provide human capital guarantee for enterprise development; implement differentiated development strategies to create a core competitiveness of the enterprise that "if anyone has, if someone has, if someone has, I will be better." Longshun Rong, which has been passed down for a hundred years, has been based on the future of Longshun Rong, which is an important mission entrusted to every Longshun Rong person by history. We must stand at the height of revitalizing national qualities and promoting Longshunrong to the world, stand at the state of saving the world, benefiting people from all directions, and relying on the excellent quality of the enterprise to win the hearts of the people in the world, and seize tomorrow and win today! The future Longshunrong will definitely be even more magnificent.
Tianjin Pharmaceutical Daren Tang Group Co., Ltd.
Sino-Singapore Tianjin Longshunrong Pharmaceutical Factory was founded in 1833. Longshunrong Pharmacy has become the leader in "Western" medicine for its excellent quality, excellent management and outstanding reputation. In 1957, Longshunrong and Lerentang Refining Department merged to form a professional manufacturer of traditional Chinese medicine extraction preparations, namely China New Pharmaceutical Tianjin Longshunrong Pharmaceutical Factory. On the basis of inheriting the fine traditions, Sino-Singapore Pharmaceutical Factory has been constantly innovating and exporting to Hong Kong, Macao, Taiwan, Singapore and Malaysia. It was once the export base of Tianjin’s Chinese patent medicines, and 21 Chinese patent medicine manufacturers across the country. one. For many years, Sino-Singapore Tianjin Longshunrong Pharmaceutical Factory has been focusing on the exploration of traditional Chinese medicine dosage form reform and the research on traditional Chinese medicine technology, and is the birthplace of the modernization of Chinese traditional Chinese medicine. It has set a precedent in the history of traditional Chinese medicine in scientific research and development, quality management, production and operation, talent citation, etc.: It established a Chinese patent medicine research institution and a national Chinese medicine refining department nationwide in 1952, and introduced a doctorate studying abroad in the history of the Chinese medicine industry. Combining traditional Chinese medicine theory with modern preparation technology to study the reform of Chinese medicine dosage form, we developed the Chinese patent medicine tablet - Yinqiao Jiedu Tablets; Chinese patent medicine tincture - Huoxiang Zhengqi Water; Chinese medicine granules - Danggui Sini Decoction; Traditional Chinese medicine injections-Jinchanlisu and other new Chinese medicine dosage forms. In terms of software construction: Sino-Singapore Tianjin Longshunrong Pharmaceutical Factory is a Chinese patent medicine manufacturer in Tianjin that promotes standardized production of all varieties of standard operation books in production quality management, forming the earliest software prototype of Chinese traditional Chinese medicine pharmaceutical companies. . Currently, Sino-Singapore Tianjin Longshunrong Pharmaceutical Factory has three production lines: liquid agent, tablet and granule, and 88 registered varieties. Under the new development situation, Sino-Singapore Pharmaceutical Tianjin Longshunrong Pharmaceutical Factory has established the corporate survival concept of " making high-quality Chinese medicine products and creating national quintessential brands ", and advocates the corporate culture with "development" as the core on the basis of integrity. Advocate the concept of " honesty management " in sales work; advocate the concept of "quality first" in production work; advocate the concept of "innovative development" in technical work; advocate the concept of "people-oriented" in human resources management work. In the development plan, the enterprise proposes: advocate a corporate culture with "innovation" as the core to maximize corporate value; provide high-quality products and services, create health for mankind and wealth for society; be responsible for employees to meet the needs of employees' lives and growth, Enable its material and spiritual interests to realize; devote themselves to social welfare undertakings, become a caring enterprise, and reflect the social value of the enterprise; inherit the culture of health medicine and create a strong brand of "Longshunrong". Longshunrong has established a reasonable talent structure to provide human capital guarantee for enterprise development; implement differentiated development strategies to create a core competitiveness of the enterprise that "if anyone has, if someone has, if someone has, I will be better." Longshun Rong, which has been passed down for a hundred years, has been based on the future of Longshun Rong, which is an important mission entrusted to every Longshun Rong person by history. We must stand at the height of revitalizing national qualities and promoting Longshunrong to the world, stand at the state of saving the world, benefiting people from all directions, and relying on the excellent quality of the enterprise to win the hearts of the people in the world, and seize tomorrow and win today! The future Longshunrong will definitely be even more magnificent.
Jilin Jill Pharmaceutical Co., Ltd.
Jilin Jierji Pharmaceutical Co., Ltd. is located in the beautiful Jiangcheng Jilin City. It is a comprehensive pharmaceutical enterprise integrating R&D, production and sales. The company was founded in 2000 and has 76 product approval numbers and 5 patented varieties. In 2017, the company moved as a whole to the "Girji Pharmaceutical and Health Industry Park" located in Jilin High-tech North District. In June 2018, it passed the drug GMP certification and started production. The project covers an area of 287,000 square meters, with a total construction area of about 200,000 square meters, and a total investment of about 1.2 billion yuan. The products cover the endocrine system, cardiovascular and cerebrovascular system, respiratory system, digestive system, gynecology, rheumatoid arthritis, tumors and anti-infection fields. At present, a product group with traditional Chinese medicine as the main one and both Chinese and Western medicines has been formed. The annual production capacity can reach 20 billion tablets, 20 billion capsules, 10 billion pills of pills, 200 million bags of granules, 1 billion bottles of oral liquid, 20 million bottles of sprays, 20 million decoction creams, 10 million glues 120 million patches, 3000 tons of formula granules. Girji Pharmaceutical takes the "health, energy conservation, environmental protection, green and high-tech" big health industry as its development concept, adheres to planning and construction with high starting point and high-level standards, and takes modern Chinese medicine and health products as the main body of production. We will strive to create a big health industry, go global, and achieve the strategic goal of "gathering global technology and building a pharmaceutical aircraft carrier".
Jilin Jill Pharmaceutical Co., Ltd.
Jilin Jierji Pharmaceutical Co., Ltd. is located in the beautiful Jiangcheng Jilin City. It is a comprehensive pharmaceutical enterprise integrating R&D, production and sales. The company was founded in 2000 and has 76 product approval numbers and 5 patented varieties. In 2017, the company moved as a whole to the "Girji Pharmaceutical and Health Industry Park" located in Jilin High-tech North District. In June 2018, it passed the drug GMP certification and started production. The project covers an area of 287,000 square meters, with a total construction area of about 200,000 square meters, and a total investment of about 1.2 billion yuan. The products cover the endocrine system, cardiovascular and cerebrovascular system, respiratory system, digestive system, gynecology, rheumatoid arthritis, tumors and anti-infection fields. At present, a product group with traditional Chinese medicine as the main one and both Chinese and Western medicines has been formed. The annual production capacity can reach 20 billion tablets, 20 billion capsules, 10 billion pills of pills, 200 million bags of granules, 1 billion bottles of oral liquid, 20 million bottles of sprays, 20 million decoction creams, 10 million glues 120 million patches, 3000 tons of formula granules. Girji Pharmaceutical takes the "health, energy conservation, environmental protection, green and high-tech" big health industry as its development concept, adheres to planning and construction with high starting point and high-level standards, and takes modern Chinese medicine and health products as the main body of production. We will strive to create a big health industry, go global, and achieve the strategic goal of "gathering global technology and building a pharmaceutical aircraft carrier".
A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
AbbVie Inc.
A biopharmaceutical company specializing in immunology, oncology, and neuroscience.
GSK is a British multinational pharmaceutical company known for its respiratory and anti-inflammatory treatments.
GlaxoSmithKline plc
GSK is a British multinational pharmaceutical company known for its respiratory and anti-inflammatory treatments.
Merck is a leading pharmaceutical company with a focus on innovative treatments, including anti-inflammatory drugs.
Merck & Co., Inc.
Merck is a leading pharmaceutical company with a focus on innovative treatments, including anti-inflammatory drugs.
Lupin is a global pharmaceutical company specializing in generic and branded medicines, including anti-inflammatory treatments.
Lupin Limited
Lupin is a global pharmaceutical company specializing in generic and branded medicines, including anti-inflammatory treatments.
Teva Pharmaceutical Industries Ltd.
Teva is a global leader in generic and specialty medicines, including anti-inflammatory treatments.
Teva Pharmaceutical Industries Ltd.
Teva is a global leader in generic and specialty medicines, including anti-inflammatory treatments.
A biopharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.
AstraZeneca PLC
A biopharmaceutical company specializing in treatments for cancer, cardiovascular, and respiratory diseases.
A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.
Roche Holding AG
A leader in pharmaceuticals and diagnostics, known for cancer treatments and diagnostic tools.
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Johnson & Johnson
A multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods.
Sanofi (China) Investment Co., Ltd.
Sanofi is a world-leading pharmaceutical and health enterprise that focuses on patient needs and research, develop and promote innovative treatment solutions. Sanofi's main business covers three areas: pharmaceuticals, human vaccines and animal health care. In 1982, Sanofi opened an office in China, becoming one of the first multinational pharmaceutical companies to enter China. Sanofi is headquartered in Shanghai in China and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi. Since entering China in 1982, Sanofi has brought more than 40 innovative drugs and vaccines to China, including key areas such as cardiovascular disease, central nervous system diseases, internal medicine diseases, diabetes, tumors and blood diseases.
Sanofi (China) Investment Co., Ltd.
Sanofi is a world-leading pharmaceutical and health enterprise that focuses on patient needs and research, develop and promote innovative treatment solutions. Sanofi's main business covers three areas: pharmaceuticals, human vaccines and animal health care. In 1982, Sanofi opened an office in China, becoming one of the first multinational pharmaceutical companies to enter China. Sanofi is headquartered in Shanghai in China and has 11 regional offices in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi. Since entering China in 1982, Sanofi has brought more than 40 innovative drugs and vaccines to China, including key areas such as cardiovascular disease, central nervous system diseases, internal medicine diseases, diabetes, tumors and blood diseases.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Pfizer Investment Co., Ltd.
Founded in 1849 and headquartered in New York, USA, Pfizer Inc. is a science-based, innovative, patient-first biopharmaceutical company. For more than 170 years, Pfizer has used scientific and global resources to provide treatment options for people to prolong their lives and significantly improve their quality of life. The global portfolio includes innovative medicines and vaccines. Every day, Pfizer employees all over the world are actively committed to promoting human health, promoting the prevention, treatment and curing of diseases, and actively responding to the current disease challenges and the chronic diseases of the times. In addition, Pfizer is working with health care providers, governments and communities to support and promote access to more reliable and affordable health care services for people around the world. This is consistent with Pfizer’s responsibility as a globally outstanding innovative biopharmaceutical company. In 1989, Pfizer entered the Chinese market. Currently, Pfizer's business in China covers more than 300 cities, with a total investment of more than US$1.5 billion, and has established an advanced production facility, 2 R&D centers (located in Shanghai Zhangjiang High-Tech Park and Wuhan Optical Valley respectively), Nearly 7,000 employees are distributed in business, R&D and production fields. Pfizer has launched high-quality innovative products in five major fields in China, including prescription drugs and vaccines in the fields of tumors, vaccines, anti-infection, inflammation and immunity, rare diseases, etc. The strong and complete product line is designed to meet the health needs of all stages of life.
Beijing Novartis Pharma Ltd.
Novartis ' history can be traced back to three companies that have intersections with it. Gargi established a trading of chemicals and dyes in Basel, Switzerland in the mid-18th century; Ciba began to produce dyes in 1859; Sandoz in 1886 2019 a chemical company was established in Basel. Later, Novartis was formed by the merger of these three companies in 1996. With its predecessor's long and rich experience in developing innovative products, it developed from its initial focus on the production and synthesis of fiber fabric dyes and became a focus on chemistry The world's largest pharmaceutical and health enterprise of product and medicine. Novartis is one of the three largest pharmaceutical companies in the world. Its headquarters is located in Basel, Switzerland. Its business covers more than 150 countries and regions around the world and has 138,000 employees. Novartis is committed to providing innovative medical and healthcare solutions to patients and society to meet their changing health needs, focusing on the four core therapeutic areas where patients need urgently (cardiovascular, kidney and metabolism, tumors, immune, neuroscience) and the five major Technology platforms (chemotherapy, biotherapy, xRNA therapy, radioligand therapy, gene and cell therapy) continue to develop pioneering therapies. It has a diversified product portfolio, with business departments including innovative drugs (Novartis), ophthalmic health care (Alcon), generic drugs (Sandus), vaccines, and animal health products. The Novartis China headquarters was established in 1997. Its name is "Promise for China", which means improving the health level and quality of life of the Chinese people through continuous innovative products and services. China is one of Novartis' major strategic markets around the world. Novartis has laid out its Chinese market from R&D, production to business development, and has built production bases in Changping, Beijing, and established R&D institutions in Beijing, Shanghai and Jiangsu. Since 1987, Novartis has approved about 100 innovative drugs and new indications in China. In order to accelerate the introduction of innovative drugs, since 2022, Novartis' new drugs and new indications in China have achieved 100% sync with the world; at the same time, Novartis actively promotes the accessibility of innovative drugs, and since 2017, more than 30 have been reported. The drug has been included in the national medical insurance catalog.
Beijing Novartis Pharma Ltd.
Novartis ' history can be traced back to three companies that have intersections with it. Gargi established a trading of chemicals and dyes in Basel, Switzerland in the mid-18th century; Ciba began to produce dyes in 1859; Sandoz in 1886 2019 a chemical company was established in Basel. Later, Novartis was formed by the merger of these three companies in 1996. With its predecessor's long and rich experience in developing innovative products, it developed from its initial focus on the production and synthesis of fiber fabric dyes and became a focus on chemistry The world's largest pharmaceutical and health enterprise of product and medicine. Novartis is one of the three largest pharmaceutical companies in the world. Its headquarters is located in Basel, Switzerland. Its business covers more than 150 countries and regions around the world and has 138,000 employees. Novartis is committed to providing innovative medical and healthcare solutions to patients and society to meet their changing health needs, focusing on the four core therapeutic areas where patients need urgently (cardiovascular, kidney and metabolism, tumors, immune, neuroscience) and the five major Technology platforms (chemotherapy, biotherapy, xRNA therapy, radioligand therapy, gene and cell therapy) continue to develop pioneering therapies. It has a diversified product portfolio, with business departments including innovative drugs (Novartis), ophthalmic health care (Alcon), generic drugs (Sandus), vaccines, and animal health products. The Novartis China headquarters was established in 1997. Its name is "Promise for China", which means improving the health level and quality of life of the Chinese people through continuous innovative products and services. China is one of Novartis' major strategic markets around the world. Novartis has laid out its Chinese market from R&D, production to business development, and has built production bases in Changping, Beijing, and established R&D institutions in Beijing, Shanghai and Jiangsu. Since 1987, Novartis has approved about 100 innovative drugs and new indications in China. In order to accelerate the introduction of innovative drugs, since 2022, Novartis' new drugs and new indications in China have achieved 100% sync with the world; at the same time, Novartis actively promotes the accessibility of innovative drugs, and since 2017, more than 30 have been reported. The drug has been included in the national medical insurance catalog.
Boehringer Ingelheim (China) Investment Co., Ltd.
Boehringer Ingelheim is committed to researching breakthrough therapies aimed at transforming lives and protecting the health of generations. As a global leading pharmaceutical company driven by R&D, the company demonstrates value through innovation in areas where medical needs are highly unmet. Boehringer Ingelheim has been an independent family business since its establishment in 1885 and has always focused on long-term development. In the three major business areas of human medicine, animal health and biopharmaceutical contract production, more than 52,000 employees worldwide serve more than 130 regions.
Boehringer Ingelheim (China) Investment Co., Ltd.
Boehringer Ingelheim is committed to researching breakthrough therapies aimed at transforming lives and protecting the health of generations. As a global leading pharmaceutical company driven by R&D, the company demonstrates value through innovation in areas where medical needs are highly unmet. Boehringer Ingelheim has been an independent family business since its establishment in 1885 and has always focused on long-term development. In the three major business areas of human medicine, animal health and biopharmaceutical contract production, more than 52,000 employees worldwide serve more than 130 regions.
